Figure 5.

Serum neutralizing anti-Ad antibody levels after i.t. and i.v. delivery of Ad/β-gal, Ad/hIL-10, or Ad/vIL-10. Anti-Ad antibody levels were reduced significantly in mice receiving either i.t. or i.v. Ad/hIL-10 and Ad/vIL-10, as compared with mice receiving Ad/β-gal, P < 0.001. The anti-Ad antibody levels that developed in both the i.t. (A) and i.v. (B) Ad/hIL-10- and Ad/vIL-10-treated animals were not increased significantly over the levels seen in mice treated with buffer alone. Buffer-treated animals had immeasurable antibody levels and were conservatively given a titer of 20, the lowest dilution factor measured.